



Telix Pharmaceuticals Limited
ACN 616 620 369
55 Flemington Road
North Melbourne
Victoria, 3051
Australia

17 March 2025

**Notice under section 708A(5)(e) of the *Corporations Act 2001*
Telix Pharmaceuticals Limited (ASX Code: TLX) (“Company”)**

Reference is made to the Appendix 2A released on 17 March 2025 and the issue of fully paid ordinary shares in Telix Pharmaceuticals Limited (**Shares**). For the purposes of section 708A(5)(e) of the Corporations Act, the Company gives notice that:

- (a) The Company issued 13,356 Shares on 17 March 2025 following satisfaction of an agreed contractual milestone related to regulatory approval of the purchased clinical decision support software AI platform as earn-out consideration for the acquisition of Dedicaid GmbH (refer to the Company’s ASX announcement dated 27 April 2023 for further details).
- (b) The Company issued the Shares without disclosure under Part 6D.2 of the Corporations Act.
- (c) As at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company and sections 674 and 674A of the Corporations Act.
- (d) As at the date of this notice, there is no information that is “excluded information” (as defined in sections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by the Company.

Authorised for release by

A handwritten signature in black ink, appearing to read 'Genevieve Ryan', written over a horizontal line.

Genevieve Ryan
Company Secretary